ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Cambrex to go private

by Michael McCoy
August 9, 2019 | APPEARED IN VOLUME 97, ISSUE 32

 

The small-molecule drug services firm Cambrex has agreed to be acquired by the private equity firm Permira in a transaction worth about $2.4 billion, including debt. Under the deal, Cambrex shareholders will receive $60 in cash per share, a 47% premium on the firm’s Aug. 6 closing stock price. Cambrex has the right to solicit acquisition proposals from other parties during a 45-day “go-shop” period. With sales last year of about $515 million, Cambrex is one of just a few pharmaceutical chemical companies to be publicly traded—and for now, the only one based in the US. It acquired two significant drug services businesses over the past year: Avista Pharma Solutions, for $252 million, and Halo Pharma, for $425 million. Permira, which already owns LSNE, a finished-drug services firm, says it will back Cambrex in its next phase of growth. If the deal is completed, Cambrex will follow AMRI, another large US-based drug chemical firm, in leaving the stock market for private ownership. In that 2017 deal, two investment firms paid $1.5 billion to take AMRI private. Although AMRI sold for a lower price, its sales at the time were greater than Cambrex’s are today.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment